A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk

Zobrazit další vydání (1)

We used baseline data from the NAVIGATOR trial to (1) identify risk factors for diabetes progression in those with impaired glucose tolerance and high cardiovascular risk, (2) create models predicting 5-year incident diabetes, and (3) provide risk classification tools to guide clinical interventions...

Podrobná bibliografie
Hlavní autoři:	Bethel, M, Chacra, A, Deedwania, P, Fulcher, G, Holman, R, Jenssen, T, Kahn, SE, Levitt, N, McMurray, J, Califf, R, Raptis, SA, Thomas, L, Sun, J, Haffner, S
Médium:	Journal article
Jazyk:	English
Vydáno:	2013

Podobné jednotky

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
Autor: Bethel, M, a další
Vydáno: (2013)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Autor: Califf, R, a další
Vydáno: (2008)

Updated risk factors should be used to predict development of diabetes.
Autor: Bethel, M, a další
Vydáno: (2017)

Prediabetes and the risk of diabetes.
Autor: McMurray, J, a další
Vydáno: (2012)

High Frequency of Unrecognized Diabetes in Cardiovascular Patients: Should All Have an Oral Glucose Tolerance Test?
Autor: Bethel, M, a další
Vydáno: (2008)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
Autor: Currie, G, a další
Vydáno: (2017)

Frequency of abnormal glucose tolerance and the metabolic syndrome in people at increased cardiovascular disease risk screened for the NAVIGATOR trial
Autor: Holman, R, a další
Vydáno: (2003)

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
Autor: McMurray, J, a další
Vydáno: (2012)

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Autor: Latini, R, a další
Vydáno: (2013)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Autor: Krum, H, a další
Vydáno: (2010)

Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR
Autor: McMurray, J, a další
Vydáno: (2004)

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
Autor: Mcmurray, J, a další
Vydáno: (2012)

Association of non-alcoholic steatothepatitis with components of the metabolic syndrome in 43,509 patients screened for NAVIGATOR
Autor: Bethel, A, a další
Vydáno: (2005)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
Autor: Mcmurray, J, a další
Vydáno: (2011)

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Autor: Preiss, D, a další
Vydáno: (2013)

Diet and other health-related behaviors of individuals with impaired glucose tolerance, cardiovascular disease (CVD) or CVD risk: A global view from the NAVIGATOR study
Autor: Bales, C, a další
Vydáno: (2013)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
Autor: Yates, T, a další
Vydáno: (2014)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
Autor: Yates, T, a další
Vydáno: (2014)

Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
Autor: Shen, L, a další
Vydáno: (2012)

Determining the most appropriate components for a composite clinical trial outcome.
Autor: Bethel, M, a další
Vydáno: (2008)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Autor: Shen, L, a další
Vydáno: (2013)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
Autor: Preiss, D, a další
Vydáno: (2012)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
Autor: Califf, R, a další
Vydáno: (2003)

Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population.
Autor: Bethel, M, a další
Vydáno: (2009)

Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial.
Autor: de Barros e Silva, P, a další
Vydáno: (2014)

Evaluation of a self-administered oral glucose tolerance test
Autor: Bethel, M, a další
Vydáno: (2013)

International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.
Autor: Dos Santos, M, a další
Vydáno: (2017)

Relations between Baseline Physical Activity by Pedometer Counts and Future Cardiovascular Events in the NAVIGATOR Study
Autor: Kraus, W, a další
Vydáno: (2012)

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
Autor: Sharma, A, a další
Vydáno: (2016)

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.
Autor: Huffman, K, a další
Vydáno: (2014)

Association of Baseline Physical Activity by Pedometer Counts and Nutritional Behavior on Metabolic Syndrome in the NAVIGATOR Study
Autor: Huffman, K, a další
Vydáno: (2013)

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial
Autor: Marilia Harumi Higuchi dos Santos, a další
Vydáno: (2017-01-01)

Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Autor: Bethel, M, a další
Vydáno: (2009)

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR
Autor: Huffman, K, a další
Vydáno: (2014)

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.
Autor: Holman, R, a další
Vydáno: (2014)

Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.
Autor: Holman, R, a další
Vydáno: (2014)

Evaluation of a self-administered oral glucose tolerance test.
Autor: Bethel, M, a další
Vydáno: (2013)

Effect of valsartan on the incidence of diabetes and cardiovascular events.
Autor: McMurray, J, a další
Vydáno: (2010)

Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Autor: Holman, R, a další
Vydáno: (2010)

Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study.
Autor: Preiss, D, a další
Vydáno: (2014)